REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
Story
FDA Approves First Drug to Treat Agitation Symptoms Associated
For Alzheimer's Agitation, Promising News from Rexulti
A first: FDA approves drug to treat agitation in Alzheimer's
Agitation in Alzheimer's: Rexulti® Makes Meaningful Improvements
Brexpiprazole Demonstrates Clinically Meaningful Improvements for
FDA Approves First Drug to Treat Alzheimer's Agitation
FDA rushes approval of dementia drug that quadruples risk of death
These highlights do not include all the information needed to use
Medicare coverage debates amplify as FDA approves Rexulti for
FDA Approves First Drug to Treat Dementia-Associated Agitation in
JAMA Neurology Publishes Complete Results of Positive Phase 3
FDA nod for Rexulti sNDA in treatment of Alzheimer's agitation
